Company intelligence / Profile preview

Zalerg

Montpellier, Occitanie, France

Ownership: Private
Development stage: Other

Overview

Zalerg was a French clinical-stage biotechnology company based in Montpellier, focused on developing innovative treatments for respiratory allergies. The company's lead candidate, ZAL-001, was a fixed-dose combination of the antihistamine levocetirizine and the leukotriene receptor antagonist montelukast. This combination was designed to provide superior efficacy in treating allergic rhinitis and asthma compared to monotherapies. Zalerg conducted Phase 2 clinical trials to evaluate the safety and efficacy of its lead program before the company was deregistered in 2021.

Therapeutic areas: ImmunologyPulmonology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Zalerg.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zalerg.

Explore the full profile